Updated on 10 July 2012
The act is a rare pediatric disease priority review voucher incentive program and addresses concerns related to conflict-of-interest regulations for advisory committee members.
Dr Saltonstall.further said that, "We are grateful for the hard work and input our member organizations and policy partners have contributed over the past two years-raising awareness among Congress, the FDA and the National Institutes of Health. NORD looks forward to continued collaborations and to support the issues that deeply affect the rare disease community."
Get direct access to more such reports. Subscribe to BioSpectrum Bureau 
Survey Box
Subscribe to BioSpectrum Asia digital mag at an attractive price of US $49.99 a year
(Includes all 24 regular & special issues @ fortnightly frequency)
Send this article by email
Australia
China
India
Japan
Korea
Malaysia
New Zealand 
Singapore
Taiwan
Thailand
